World Health Organization - CANNABIDIOL (CBD)Pre-Review Report
Listed below is an excerpt from a report from: WHO - CANNABIDIOL (CBD) Pre-Review Report Agenda Item 5.2. The table associated with the report as listed below defines potential benefits from CBD as presented by WHO.
"The range of conditions for which CBD has been assessed is diverse, consistent with its neuroprotective, antiepileptic, hypoxia-ischemia, anxiolytic, antipsychotic, analgesic, anti-inflammatory, anti-asthmatic, and antitumor properties.[37, 50, 67] The evidence for CBD’s various therapeutic applications was recently reviewed by Pisanti et al (2017), refer to Table 1."
Table 1. Overview of diseases for which CBD may have therapeutic benefits taken from Pisanti et al (2017)  Disease Effects Alzheimer's disease Antinflammatory, antioxidant, antiapoptotic in in vitro and in vivo models of Aβ-evoked neuroinflammatory and neurodegenerative responses. Parkinson's disease Attenuation of the dopaminergic impairment in vivo; neuroprotection; improvement of psychiatric rating and reduction of agitation, nightmare and aggressive behaviour in patients. Multiple sclerosis Improved signs of EAE in mice, antinflammatory and immunomodulatory properties Huntington's disease Neuroprotective and antioxidant in mice transgenic models; no significant clinically important differences in patients. Hypoxia-ischemia injury Short term neuroprotective effects; inhibition of excitotoxicity, oxidative stress and inflammation in vitro and in rodent models. Pain Analgesic effect in patients with neuropathic pain resistant to other treatments. Psychosis Attenuation of the behavioural and glial changes in animal models of schizophrenia; anti-psychotic properties on ketamine-induced symptoms Anxiety Reduction of muscular tension, restlessness, fatigue, problems in concentration, improvement of social interactions in rodent models of anxiety and stress; reduced social anxiety in patients. Depression Anti-depressant effect in genetic rodent model of depression. Cancer Antiproliferative and anti-invasive actions in a large range of cancer types; induction of autophagy-mediated cancer cell death; chemopreventive effects. Nausea Suppression of nausea and conditioned gaping in rats Inflammatory diseases Antinflammatory properties in several in vitro and in vivo models; inhibition of inflammatory cytokines and pathways. Rheumatoid
Inhibition of TNF-α in an animal model Infection Activity against methicillin-resistant Staphylococcus aureus Inflammatory
bowel and Crohn's
Inhibition of macrophage recruitment and TNF-α secretion in vivo and ex vivo; reduction in disease activity index in Crohn's patients. Cardiovascular diseases Reduced infarct size through anti-oxidant and anti-inflammatory properties in vitro and in vivo. Diabetic complications Attenuation of fibrosis and myocardial dysfunction